Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-126 in Cognitive Deficits in Schizophrenia (Nonsmokers)
NCT01655680Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of nelonicline in schizophrenia, sponsored by AbbVie Inc.. Started May 2012; status: completed.
02
Drugs
nelonicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01655680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01655680.